paroxetine has been researched along with atomoxetine hydrochloride in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fuller, RW; Gehlert, DR; Hemrick-Luecke, SK; Howbert, JJ; Krushinski, J; Robertson, DW; Schober, DA; Wong, DT | 1 |
| Bymaster, FP; Krushinski, JH; Mayle, DA; Reid, LR; Robertson, DW; Wong, DT | 1 |
| Benvenga, MJ; Dreshfield, L; Fuller, RW; Gehlert, DR; Gleason, S; Hemrick-Luecke, SK; Tinsley, F; Wong, DT | 1 |
| Belle, DJ; Ernest, CS; Sauer, JM; Smith, BP; Thomasson, HR; Witcher, JW | 1 |
| Clement, HW; Gründer, G; Paulzen, M | 1 |
| Aldosary, F; Blier, P; James, JS; Norris, S; Ritchie, JC; Tremblay, P | 1 |
1 trial(s) available for paroxetine and atomoxetine hydrochloride
| Article | Year |
|---|---|
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.
Topics: Administration, Oral; Adult; Area Under Curve; Atomoxetine Hydrochloride; Blood Pressure; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Female; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Phenols; Phenyl Ethers; Propylamines; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Symporters; Time Factors | 2002 |
6 other study(ies) available for paroxetine and atomoxetine hydrochloride
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Brain; Hypothalamus; Male; Norepinephrine; Oxidopamine; Paroxetine; Propylamines; Protein Binding; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Synaptosomes | 1995 |
Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.
Topics: Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Brain; Dose-Response Relationship, Drug; Fluoxetine; Male; Paroxetine; Propylamines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Stereoisomerism | 1993 |
The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Carrier Proteins; Eating; Fluoxetine; Male; Mice; Mice, Inbred ICR; Motor Activity; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Paroxetine; Propylamines; Rats; Rats, Sprague-Dawley; Symporters | 1998 |
Enhancement of atomoxetine serum levels by co-administration of paroxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Male; Paroxetine; Propylamines | 2008 |
Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
Topics: Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Cyclohexanols; Depressive Disorder, Major; Humans; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Tyramine; Venlafaxine Hydrochloride | 2022 |